North America Heart Pump Device Market Size & Forecast (2025–2033)

The North America Heart Pump Device Market is on a strong growth trajectory, expected to rise from US$ 2.92 billion in 2024 to US$ 8.1 billion by 2033, registering a robust CAGR of 12% between 2025 and 2033. This momentum is driven by technological advancements in cardiac care, the rising incidence of cardiovascular diseases, and a rapidly expanding geriatric population across the region—factors which collectively fuel demand for advanced mechanical circulatory support systems.

North America Heart Pump Device Market Outlook

A heart pump device is a mechanical system used to support or enhance the function of the heart in patients with advanced cardiovascular diseases, particularly those with severe heart failure. Devices such as Left Ventricular Assist Devices (LVADs), Intra-Aortic Balloon Pumps (IABPs), and Total Artificial Hearts (TAHs) are deployed to stabilize cardiac function, improve blood flow, and sustain life in patients awaiting transplantation or those who are ineligible for surgery.

These devices play a critical role in:

• Alleviating heart failure symptoms such as fatigue and dyspnea
• Supporting high-risk surgical procedures
• Providing life-sustaining therapy for end-stage heart disease
• Aiding post–myocardial infarction recovery

North America’s high burden of cardiovascular disease—driven by lifestyle factors and an aging populace—has amplified the demand for heart pump solutions. Continued advancements such as miniaturized pumps, wireless technology, and implantable systems are improving safety, usability, and clinical outcomes, further promoting market adoption.

Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=north-america-heart-pump-device-market-p.php

Key Growth Drivers in the North America Heart Pump Device Market

1. Rising Prevalence of Cardiovascular Diseases

Cardiovascular disease remains the leading cause of death across North America. Conditions including heart failure, coronary artery disease, congenital defects, and arrhythmias continue to rise.

Key statistics include:

• 919,032 deaths in the U.S. in 2023 were attributed to cardiovascular disease—1 in every 3 deaths.
• Canada’s senior population (65+) is projected to rise from 5% in 2021 to up to 29.8% by 2068, significantly increasing the burden of heart disease.

Aging remains one of the strongest risk factors for heart failure. Additionally, rising cases of hypertension, diabetes, obesity, and sedentary habits are accelerating the demand for advanced cardiac support devices.

Patients with advanced disease often require mechanical circulatory support systems such as VADs, IABPs, or ECMO. As diagnosis and screening improve, greater numbers of patients are identified earlier and referred for life-saving interventions, driving market growth.

2. Technological Innovations in Heart Pump Devices

Rapid innovation in structural design, miniaturization, and biocompatible materials is significantly improving patient outcomes. Current trends include:

• Fully implantable VADs
• Percutaneous heart pumps for short-term support
• Wireless energy transmission reducing infection risks
• Remote monitoring features for real-time patient tracking
• Improved battery longevity

Technological progress is expanding the population that can benefit from heart pump therapy.

Key Industry Milestone:
In December 2024, the U.S. FDA expanded indications for Johnson & Johnson MedTech’s Impella 5.5 with SmartAssist and Impella CP with SmartAssist pumps to include pediatric patients suffering from symptomatic acute decompensated heart failure and cardiogenic shock. This marks a notable expansion in the devices’ clinical use and highlights momentum in regulatory approvals.

Further innovations reduce complications like thrombosis, infection, and mechanical failure, encouraging wider clinical adoption in both the U.S. and Canada.

3. Supportive Reimbursement and Healthcare Infrastructure

North America’s advanced healthcare systems provide strong backing for cardiac device adoption:

United States

• Medicare, Medicaid, and private insurers cover a broad range of advanced cardiac interventions, including VAD implantation and IABP support.
• High investment in specialized cardiac centers encourages rapid adoption of next-generation devices.

Canada

• Universal healthcare ensures equitable access to advanced cardiac therapies, including mechanical circulatory support.
• Publicly funded hospitals are increasingly adopting VADs and IABPs for eligible patients.

Continuous physician training, government-led cardiac care initiatives, and strong clinical trial infrastructure in both countries support growing device deployment and improved outcomes.

Challenges in the North America Heart Pump Device Market

1. High Cost of Devices and Procedures

Heart pump devices are sophisticated, high-cost systems requiring specialized surgical implantation and long-term healthcare support.

Cost barriers include:

• Tens of thousands of dollars for VAD acquisition
• Significant hospitalization and surgical fees
• Costs associated with managing complications
• Ongoing maintenance and monitoring

Despite reimbursement, many patients face high out-of-pocket expenses, limiting the market’s reach—particularly among low-income groups. Hospitals too face budgetary constraints as device procurement and maintenance are costly.

2. Device-Related Risks and Complications

While heart pump devices save lives, they present potential risks, including:

• Infection at the implantation site
• Blood clots and stroke
• Bleeding complications
• Mechanical failures
• Need for replacement surgeries

Patients require lifelong monitoring and strict adherence to medical protocols. These challenges limit adoption among moderate heart failure patients and can also make clinicians cautious in recommending device therapy.

North America Heart Pump Device Market Landscape

North America is one of the most advanced regions for cardiovascular treatment, supported by:

• Strong medical device R&D
• High healthcare spending
• Specialized cardiac centers
• Regulatory advancements

The United States leads the market, with Canada following closely due to universal healthcare coverage.

Acceptance of VADs, IABPs, extracorporeal heart pumps, and TAHs continues to grow across hospitals and cardiac care centers.

Despite high costs and risks, the trajectory remains upward as newer-generation devices reduce clinical complications and improve survival rates.

Segment-Level Insights

North America Ventricular Assist Devices (VADs) Market

VADs are witnessing strong adoption due to rising end-stage heart failure cases. Uses include:

• Bridge to transplant
• Destination therapy for non-transplant candidates
• Bridge to recovery

Miniaturized and durable VADs with enhanced biocompatibility fuel adoption. U.S. reimbursement coverage accelerates usage, while Canada leverages government-funded systems to ensure accessibility.

However, high cost and risks like bleeding or thrombosis remain limiting factors.

North America Intra-Aortic Balloon Pumps (IABPs) Market

IABPs continue to play a vital role in treating:

• Acute myocardial infarction
• Cardiogenic shock
• Acute decompensated heart failure

Their advantages include:

• Lower invasiveness
• Affordability
• Effective short-term support

Despite competition from percutaneous pumps, IABPs remain widely used across emergency departments and critical care units in the U.S. and Canada.

North America Implanted Heart Pump Device Market

Implantable devices—primarily VADs—play a central role in long-term treatment of chronic heart failure. The U.S. dominates due to high transplant demand and advanced destination therapy programs.

Technological breakthroughs such as:

• Wireless charging
• Miniaturized implants
• Improved durability

are improving adoption. Canada shows consistent growth, supported by public healthcare mechanisms, though adoption is slower due to budget and regulatory constraints.

North America Heart Pump Device Hospitals Market

Hospitals account for the largest share due to:

• Availability of specialized cardiologists
• Advanced surgical infrastructure
• Favorable reimbursement
• Access to clinical trials for next-gen devices

Both U.S. and Canadian hospitals heavily utilize VADs and IABPs, making this segment the backbone of the heart pump device market.

North America Heart Pump Device Cardiac Centers Market

Dedicated cardiac centers play a strategic role by:

• Managing complex cases
• Offering advanced surgical procedures
• Running investigational device trials
• Providing individualized patient care

These centers enhance recovery outcomes and drive high adoption of mechanical circulatory support systems.

Country Analysis

USA Heart Pump Device Market

The United States leads the regional market due to:

• High cardiovascular disease prevalence
• Advanced healthcare expenditure
• Reimbursement support
• Strong presence of global medtech companies
• Access to clinical innovation

Recent Development:
In January 2025, surgeons at the University of Michigan implanted a patient with a novel mechanical heart pump in a clinical trial comparing it to current end-stage heart failure treatments. This milestone underscores ongoing innovation and expanding treatment options.

Canada Heart Pump Device Market

Canada’s market is growing steadily, supported by:

• Universal healthcare coverage
• Increasing aging population
• Rising obesity and diabetes rates
• Equitable access to VADs and IABPs

Industry Update:
In August 2024, Abbott received FDA approval for a label update on the HeartMate 3™ LVAD, eliminating the need for aspirin in standard treatment protocols—changes recognized in Canada and the EU as well.

Market Segmentation

By Product

• Ventricular Assist Devices (VADs)
• Intra-Aortic Balloon Pumps (IABPs)
• Extracorporeal Membrane Oxygenation (ECMO)
• Total Artificial Hearts (TAHs)

By Type

• Implanted Heart Pump Device
• Extracorporeal Heart Pump Device

By End Use

• Hospitals
• Cardiac Centers
• Research Institutes

By Region

• United States
• Canada
• Rest of North America

Key Players (Analyzed Across 5 Viewpoints)

Overview | Key Person | Recent Developments | SWOT | Revenue Analysis

• Abbott Inc.
• Getinge AB
• Teleflex Incorporated
• Fresenius SE & Co. KGaA
• LivaNova PLC
• CorWave SA
• Jarvik Heart, Inc.
• ABIOMED

These companies are at the forefront of developing next-generation mechanical circulatory support devices, backed by robust R&D pipelines and regulatory approvals.

Conclusion

The North America Heart Pump Device Market is poised for strong and sustained expansion, expected to reach US$ 8.1 billion by 2033. Demand will continue rising due to increasing cardiovascular disease prevalence, an aging population, supportive reimbursement systems, and rapid technological advancements in mechanical heart support.

As next-generation devices become smaller, safer, and more efficient, adoption will accelerate across hospitals and cardiac centers, significantly improving survival and quality of life for patients with advanced heart failure.